

artwork - 100%

← Unwinding Direction

Each film coated tablet contains:
Sofosbuvir 400 mg
Velpatasvir 100 mg
 Do not store above 30°C.
 Store in the original container.
Dosage: As directed by the physician.
NOT TO EXCEED PRESCRIBED DOSAGE.
KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.
Indications, Warnings & Precautions:
 Read the package leaflet before use.
Warning: Formulation Contains Lactose.
Chaque comprimé pelliculé contient:
Sofosbuvir 400 mg
Velpatasvir 100 mg
 À conserver à une température ne dépassant pas 30°C.
 À conserver dans l'emballage d'origine.
Posologie: Comme dirigé par votre médecin.
NE PAS DÉPASSER LA DOSE PRESCRITE.
TENIR HORS DE LA PORTÉE ET DE LA VUE DES ENFANTS.
Indications, Mises en garde et Précautions:
 Lire la notice avant utilisation.
Mises en garde: Ce médicament contient du lactose.

MyHep ALL™
Sofosbuvir and Velpatasvir
Film Coated Tablets/ Comprimés Pelliculé
400 mg/100 mg
 POM | Schedule 2 | PP
Mylan Mylan.com
 28 Tablets/Comprimés

Tanzania Regn No.:
 Zambia Regn No.:
 Zimbabwe Regn No.:
 Botswana Regn No.:
 Namibia Regn No.:
 Namibia Scheduling Status: NS2
 NAFDAC Regn No.: B4-9581
 Myanmar Regn No.: 2311AA4073
 Mfg. Lic. No./Lic. Fab. No.: NKD/89

Mfd. by: / Fab. par:
Mylan Laboratories Limited
 F-4 & F-12, MIDC, Malegaon, Sinnar,
Mylan Nashik - 422 113, Maharashtra, INDIA
 ™ Trademark owned by Mylan

To respect prescribed doses
 Respecter les doses prescrites

75067283

(40 x 16 mm)
 Varnish Free area for
 Variable Data Coding

TO BE CODED
 BATCH LOT
 MFD FAB
 EXP

artwork - 150%

Each film coated tablet contains:
Sofosbuvir 400 mg
Velpatasvir 100 mg
 Do not store above 30°C.
 Store in the original container.
Dosage: As directed by the physician.
NOT TO EXCEED PRESCRIBED DOSAGE.
KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.
Indications, Warnings & Precautions:
 Read the package leaflet before use.
Warning: Formulation Contains Lactose.
Chaque comprimé pelliculé contient:
Sofosbuvir 400 mg
Velpatasvir 100 mg
 À conserver à une température ne dépassant pas 30°C.
 À conserver dans l'emballage d'origine.
Posologie: Comme dirigé par votre médecin.
NE PAS DÉPASSER LA DOSE PRESCRITE.
TENIR HORS DE LA PORTÉE ET DE LA VUE DES ENFANTS.
Indications, Mises en garde et Précautions:
 Lire la notice avant utilisation.
Mises en garde: Ce médicament contient du lactose.

MyHep ALL™
Sofosbuvir and Velpatasvir
Film Coated Tablets/ Comprimés Pelliculé
400 mg/100 mg
 POM | Schedule 2 | PP
Mylan Mylan.com
 28 Tablets/Comprimés

Tanzania Regn No.:
 Zambia Regn No.:
 Zimbabwe Regn No.:
 Botswana Regn No.:
 Namibia Regn No.:
 Namibia Scheduling Status: NS2
 NAFDAC Regn No.: B4-9581
 Myanmar Regn No.: 2311AA4073
 Mfg. Lic. No./Lic. Fab. No.: NKD/89

Mfd. by: / Fab. par:
Mylan Laboratories Limited
 F-4 & F-12, MIDC, Malegaon, Sinnar,
Mylan Nashik - 422 113, Maharashtra, INDIA
 ™ Trademark owned by Mylan

To respect prescribed doses
 Respecter les doses prescrites

75067283

(40 x 16 mm)
 Varnish Free area for
 Variable Data Coding

Mylan Laboratories Limited Packaging Development	Artwork Implementation Schedule Check (✓) whichever is applicable (Approval is not valid without following details)					Date of Issue		Issued By			
						Date of Return					
<input type="checkbox"/> New Component <input type="checkbox"/> Immediately (Stock of superseded component to be destroyed, if applicable.) <input type="checkbox"/> After consumption of existing (superseded) stock. <input type="checkbox"/> Other (Specify)		Material Code	75067283	Supersedes	75059692	Market	Emerging				
		Description	LBST MYHEP ALL 400 mg/100 mg 28's A/F EM V1								
		Component	Printed Self Adhesive Label	Actual Size	110 x 40 mm						
		Substrate	80gsm Chromoart Paper + (62gsm Silicon Release Liner or 32gsm PET Release Liner) + 18gsm Adhesive with Spot Aqua Varnish								
		Design & Style	Supply In-Roll (Unwinding from Right to left)								
		Reason for Issue	Inclusion of Myanmar and NAFDAC Regn. No.								
		Printing Pantone Nos	1	Black	2	306 c	3	484 c	4	179 c	
		Non Printing	5	032 c	6	NA	7	NA	8	NA	
Proof No.	1	2	3	4	5	Prepared By		Checked By		Approved By	
Date	11.02.2019	20.02.2019	dd/mm/yy	dd/mm/yy	dd/mm/yy	Packaging Development		Packaging Development		Production	
Remarks	Revised a/w.	Correction	x	x	x					Regulatory Affairs	
										Quality Assurance	
Format No.: MLNSK-SOP-PK-GEN-0001-A01-01-12-11			Final Date		dd-mm-yy						